

Assessment of the bioavailability of a poorly water-soluble drug, HGR4113 using a stable isotope tracer for preclinical drug development

Eun Ji Ha^{1, †}, Jeong In Seo^{1, †}, Shaheed Ur Rehman², Hyung Soon Park³, Sang-Ku Yoo³, Hye Hyun Yoo^{1,*}




Figure S1. Study flow chart

Supplementary data




Figure S2. Chemical structures of (A) HGR4113, (B) HGR4113-d7 and (C) HSG4112 (IS)

Supplementary data

Table S1. Results of HGR4113 and HGR4113-d7 linearity in rat plasma (n=3)

| Compound | Nominal concentration (ng/mL) | Measured concentration (ng/mL) | Regression equation | Accuracy (%) | Precision (%) |
|------------|-------------------------------|--------------------------------|----------------------------------|--------------|---------------|
| HGR4113 | 10 | 10.3±0.2 | $m^*=0.0014$ ± 0.0000 | 102.7 | 1.7 |
| | 20 | 19.3±1.1 | | 96.3 | 4.8 |
| | 50 | 46.5±5.9 | | 93.1 | 10.3 |
| | 100 | 102.6±3.2 | $b^{**}=-0.0024$ ± 0.0023 | 102.6 | 2.5 |
| | 250 | 253.7±11.3 | | 101.5 | 3.7 |
| | 500 | 548.6±12.0 | | 109.7 | 1.8 |
| | 1000 | 1082.9±36.6 | $R^{***}=0.9917$ ± 0.0001 | 108.3 | 2.8 |
| | 4000 | 3709.8±109.1 | | 92.7 | 2.5 |
| | 8000 | 7452.7±562.6 | | 93.2 | 6.2 |
| HGR4113-d7 | 5 | 5.1±0.2 | $m^*=0.0015$ | 101.3 | 4.1 |
| | 10 | 10.1±0.8 | ± 0.0001 | 100.7 | 7.8 |
| | 25 | 23.5±0.6 | | 93.9 | 2.5 |
| | 50 | 48.8±1.6 | $b^{**}=-0.0026$ | 97.6 | 3.3 |
| | 100 | 101.9±4.8 | ± 0.0011 | 101.9 | 4.7 |
| | 250 | 267.4±7.9 | | 107.0 | 3.0 |
| | 500 | 534.1±5.9 | $R^{***}=0.9934$ | 106.8 | 1.1 |
| | 1000 | 914.4±20.3 | ± 0.0012 | 91.4 | 2.2 |

*: m=slope, **: b=y-intercept, ***: R²=linear regression coefficient

Supplementary data

Table S2. Stability for HGR4113 and HGR4113-d7 in rat plasma (n=3)

| Compound | Storage condition | Nominal concentration n (ng/mL) | Measured concentration n (ng/mL) | Accuracy (%) | CV (%) |
|------------|-------------------|---------------------------------------|--|----------------|-------------|
| HGR4113 | Freeze and thaw | 30 6000 | 29.5±1.7 5920.9±276.7 | 98.4 98.7 | 5.9 4.7 |
| | Short term | 30 6000 | 30.8±3.3 5444.3±140.2 | 102.8 90.7 | 10.8 2.6 |
| | Long term | 30 6000 | 30.4±0.8 6122.5±160.1 | 101.3 102.0 | 2.6 2.6 |
| | Processed sample | 30 6000 | 27.5±0.9 6102.2±171.7 | 91.7 101.7 | 3.3 2.8 |
| | Freeze and thaw | 15 800 | 14.7±1.0 901.3±8.3 | 97.8 112.7 | 6.6 0.9 |
| | Short term | 15 800 | 13.5±0.3 886.4±3.4 | 90.2 110.8 | 2.4 0.4 |
| | Long term | 15 800 | 14.6±1.1 845.5±24.6 | 97.1 105.7 | 7.8 2.9 |
| HGR4113-d7 | Processed sample | 15 800 | 14.8±0.7 896.8±22.3 | 98.7 112.1 | 4.8 2.5 |

Supplementary data

Table S3. Pharmacokinetic parameters of HGR4113 after IV administration of 1 mg/kg (n=5) and PO administration of 10, 30 and 100 mg/kg (n=5)

| PK Parameter | IV 1 mg/kg | PO 10 mg/kg | PO 30 mg/kg | PO 100 mg/kg |
|------------------------------|------------|-------------|-------------|--------------|
| T _{max} (h) | 0.12±0.07 | 2.21±1.59 | 3.60±1.50 | 4.40±0.80 |
| C _{max} (µg/mL) | 0.13±0.02 | 0.08±0.04 | 0.56±0.27 | 2.27±0.55 |
| AUC _{0-t} (µg·h/mL) | 0.26±0.04 | 0.36±0.16 | 3.00±1.70 | 22.38±6.36 |
| T _{1/2} (h) | 2.08±0.88 | 4.37±1.55 | 2.63±1.14 | 6.04±1.33 |
| AUC _{0-∞} (µg·h/mL) | 0.28±0.03 | 0.42±0.16 | 3.03±1.70 | 24.67±7.21 |
| MRT _{last} (h) | 2.08±0.24 | 3.99±0.65 | 4.74±1.03 | 7.96±0.97 |
| Cl (L/hr/kg) | 3.63±0.42 | | | |
| Vz (L/kg) | 11.9±5.74 | | | |
| F (%) | | 13.64 | 37.96 | 84.99 |